Aarti Pharmalabs Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Revenue from operations fell 8.66% YoY to Rs 418.33 crore in the quarter ended 30 September 2025.

Profit before tax (PBT) stood at Rs 38.69 crore in Q2 FY26, down 46.09% from Rs 71.77 crore in the same period last year.

Total expenses decreased 2.99% to Rs 379.05 crore in Q2 FY26, compared to Rs 379.05 crore in Q2 FY26. The cost of materials consumed stood at Rs 203.46 crore (down 4.91% YoY), employee benefit expenses were Rs 43.41 crore (up 15.05% YoY) and finance costs stood at Rs 10.67 crore (up 93.64% YoY) during the period under review.

On half-year basis, the company's consolidated net profit climbed 29.64% to Rs 77.45 crore on 20.62% decrease in revenue to Rs 804.53 crore in H1 FY26 over H1 FY25.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.

Powered by Capital Market - Live News

Net profit of Aarti Pharmalabs declined 48.88% to Rs 27.92 crore in the quarter ended September 2025 as against Rs 54.62 crore during the previous quarter ended September 2024. Sales declined 8.67% to Rs 418.33 crore in the quarter ended September 2025 as against Rs 458.03 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 9 November 2025.

Powered by Capital Market - Live News

According to an exchange filing, the company confirmed that it has received all necessary approvals and permissions to commence operations at the site. Phase 1 includes a total reactor capacity of 440 kilolitres (kL), with 63 reactors.

The greenfield facility spans 80 acres and is designed for significant scalability, with potential to expand capacity up to 8?10 times that of Phase 1 in the future.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.

The company reported a 10.73% decline in consolidated net profit to Rs 49.50 crore in Q1 FY26, compared to Rs 55.45 crore posted in Q1 FY25. Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025.

Powered by Capital Market - Live News